UK markets closed

Travere Therapeutics, Inc. (17R.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
17.300.00 (0.00%)
As of 07:39PM CEST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
145,238
145,238
109,460
131,836
198,321
Cost of revenue
11,450
11,450
4,420
3,818
6,126
Gross profit
133,788
133,788
105,040
128,018
192,195
Operating expenses
Research development
244,990
244,990
227,333
201,159
131,773
Selling general and administrative
265,542
265,542
197,520
126,284
135,799
Total operating expenses
510,532
510,532
424,853
327,443
267,572
Operating income or loss
-376,744
-376,744
-319,813
-199,425
-75,377
Interest expense
11,334
11,334
11,014
19,682
19,050
Total other income/expenses net
-9,800
-9,800
-6,604
231
-99,366
Income before tax
-376,110
-376,110
-331,155
-216,883
-188,790
Income tax expense
223
223
313
409
-19,359
Income from continuing operations
-376,333
-376,333
-331,468
-217,292
-169,431
Net income
-111,399
-111,399
-278,482
-180,091
-169,431
Net income available to common shareholders
-111,399
-111,399
-278,482
-180,091
-169,431
Basic EPS
-
-
-
-
-3.56
Diluted EPS
-
-
-
-
-3.56
Basic average shares
-
-
-
-
47,540
Diluted average shares
-
-
-
-
47,540